Payment overview · 2025
General Payments
$412.11
15 reported records · 12 companies
Healthcare provider profile · identity verified
Shawn E Kidder, DO
Allopathic & Osteopathic Physicians|Family Medicine · WARSAW, IN · NPI 1831151869
Verified facts
What the public records show
CMS Open Payments records show Shawn E Kidder, DO received $412.11 in general payments during 2025 across 15 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 44.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $184.06 | 44.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.68 | 10.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.80 | 5.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.77 | 5.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.96 | 5.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.43 | 5.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.17 | 4.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.92 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.66 | 4.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.62 | 3.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.59 | 3.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.45 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $412.11 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $204.49 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.68 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 152 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
152 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 448 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 110 |
| Lisinopril | Lisinopril | 375 | 115 |
| Omeprazole | Omeprazole | 303 | 108 |
| Losartan Potassium | Losartan Potassium | 280 | 94 |
| Furosemide | Furosemide | 229 | 84 |
| Metformin Hcl | Metformin Hcl | 217 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 57 |
| Potassium Chloride | Potassium Chloride | 191 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 56 |
| Carvedilol | Carvedilol | 162 | 51 |
| Eliquis | Apixaban | 152 | 46 |
| Gabapentin | Gabapentin | 147 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 46 |
| Famotidine | Famotidine | 144 | 45 |
| Celecoxib | Celecoxib | 137 | 49 |
| Trazodone Hcl | Trazodone Hcl | 134 | 45 |
| Meloxicam | Meloxicam | 121 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 42 |
| Prednisone | Prednisone | 108 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 26 |
| Azithromycin | Azithromycin | 101 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 31 |
| Simvastatin | Simvastatin | 93 | 32 |
| Spironolactone | Spironolactone | 91 | 33 |
| Allopurinol | Allopurinol | 88 | 29 |
| Ozempic | Semaglutide | 87 | 24 |
| Ezetimibe | Ezetimibe | 86 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 28 |
| Metformin Hcl Er | Metformin Hcl | 84 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 25 |
| Glimepiride | Glimepiride | 81 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 20 |
| Atenolol | Atenolol | 78 | 23 |
| Cephalexin | Cephalexin | 77 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 34 |
| Montelukast Sodium | Montelukast Sodium | 77 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 25 |
| Sertraline Hcl | Sertraline Hcl | 70 | 25 |
| Januvia | Sitagliptin Phosphate | 68 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 23 |
| Glipizide | Glipizide | 60 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 31 |
| Nitroglycerin | Nitroglycerin | 56 | 43 |
| Pregabalin | Pregabalin | 56 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 15 |
| Mounjaro | Tirzepatide | 54 | 11 |
| Alendronate Sodium | Alendronate Sodium | 53 | 15 |
| Jardiance | Empagliflozin | 52 | 16 |
| Buspirone Hcl | Buspirone Hcl | 51 | 25 |
| Irbesartan | Irbesartan | 50 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 15 |
| Enalapril Maleate | Enalapril Maleate | 46 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 20 |
| Fluconazole | Fluconazole | 41 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 18 |
| Mupirocin | Mupirocin | 39 | 27 |
| Lansoprazole | Lansoprazole | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Amoxicillin | Amoxicillin | 36 | 30 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Finasteride | Finasteride | 36 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 12 |
| Levofloxacin | Levofloxacin | 33 | 27 |
| Bumetanide | Bumetanide | 32 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 13 |
| Mirtazapine | Mirtazapine | 31 | 12 |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | 12 |
| Linzess | Linaclotide | 30 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 16 |
| Valsartan | Valsartan | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 27 |
| Olanzapine | Olanzapine | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 12 |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 15 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | 24 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | 13 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Nystatin | Nystatin | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | 15 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Ofev | Nintedanib Esylate | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $412.11 · 15 records | Otsuka America Pharmaceutical, Inc. | Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, INSPIRE, Kerendia, NURTEC ODT, Ozempic, QULIPTA, REPATHA, REXULTI, SPRAVATO, UBRELVY, Veozah, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error